Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

them from dividing. Monoclonal antibodies, such as bevacizumab, and small molecule tyrosine kinase inhibitors, such as lapatinib, can block tumor growth in different ways. Some block the ability of

  • 155 views
  • 07 Nov, 2020
  • 8 locations
Lapatinib Plus Trametinib in KRAS Mutant NSCLC

This is an open-label phase I/II multi-center study consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of lapatinib combined with

KRAS
metastasis
ki-ras
lung cancer
PIK3CA
  • 39 views
  • 07 Nov, 2020
  • 1 location
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

This is a randomized controlled trial of HER-2 positive breast cancer patients treated with lapatinib and paclitaxel vs herceptin and paclitaxel with sequential and synchronous anthracycline

paclitaxel
herceptin
primary tumor
cancer
her-2 positive breast cancer
  • 42 views
  • 08 Nov, 2020
  • 1 location
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

This is a prospective, open-label, real-word study evaluating the efficacy and safety of lapatinib in combination with chemotherapy versus trastuzumab in combination with chemotherapy in women

paclitaxel
cyclophosphamide
erbb2
cancer
ejection fraction
  • 29 views
  • 08 Nov, 2020
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Recent clinical studies have shown that the combination of lapatinib and trastuzumab has superior antitumor activity compared to either single drug in both neoadjuvant and metastatic setting

erbb2
immunological adjuvant
anthracyclines
platelet count
measurable disease
  • 21 views
  • 07 Nov, 2020
  • 2 locations
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

cancer. The only treatment arm consists of Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks.

paclitaxel
carcinoma of the breast
metastasis
cancer
cish
  • 8 views
  • 07 Nov, 2020
  • 3 locations
Olaparib+Trastuzumab in HER2[+] Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

This is a multicenter, open-label, single-arm, phase II clinical trial, phase II trial will evaluate the efficacy and safety of olaparib plus trastuzumab in patients with HER2[+], BRCA-mutated advanced breast cancer

herceptin
metastasis
blood transfusion
tamoxifen
ct scan
  • 6 views
  • 09 Dec, 2020
  • 27 locations
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

This is a randomized, open-label, multi-center, Phase II clinical study to evaluate the efficacy and safety of margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in Chinese patients (Mainland, Hong Kong and Taiwan) with advanced HER2+ breast cancer who have received at least 2 prior lines of anti-HER2 directed therapy …

metastasis
neutrophil count
endocrine therapy
platelet count
lapatinib
  • 3 views
  • 16 Feb, 2020
  • 1 location
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma

In chordoma cell lines and patient biopsies, the p16 (CDKN2A) tumor suppressor is consistently deleted. Thus, chordomas are an example of a tumor with universal activation of the cyclin-dependent kinases 4 and 6 (CDK4/6) pathway, and experiments with patient-derived chordoma cell lines demonstrate aberrant CDK4/6 activity downstream of p16 loss …

imatinib
lapatinib
metastatic chordoma
vasectomy
sorafenib
  • 33 views
  • 08 Nov, 2020
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily oral dose), given in combination with trastuzumab administered through the vein, in patients with HER2-amplified Metastatic Breast Cancer that has gotten …

metastasis
growth factor
cancer
ejection fraction
cancer chemotherapy
  • 36 views
  • 16 Feb, 2020
  • 1 location